|
Funding and clinical trial-based barriers must be addressed to ensure success on the path to developing a DMT for Parkinson’s.
|
 |
|
Arexvy will now compete for market share with Pfizer’s Abrysvo and Moderna’s mRESVIA in this expanded, high-risk adult population.
|
|
|
Cosentyx’s IL-17A mechanism provides a differentiated approach for HS in younger patients.
|
|
|
The collaboration builds on Biophytis' ongoing partnership with LynxKite and aligns with Singapore’s research, innovation and enterprise (RIE) 2030 plan.
|
|
|
WHO’s director of antimicrobial resistance, Dr Yvan Hutin, says science needs to catch up with drug-resistant bacteria.
|
|
